Or Filter by:

General Inquiries

Elanco Animal Health
2500 Innovation Way
Greenfield, IN 46140 USA

1-877-ELANCO1

(1-877-352-6261)

Media Contacts

Questions?
Contact us.



Our Global Offices

Follow Elanco

07-MAY-2020

Elanco Animal Health Reports 2020 First Quarter Results

Post by: Colleen Parr Dekker

  • Total Revenue was $657.7 million, a decrease of 10 percent. On a constant currency basis, Total Revenue declined 9 percent due to a reduction of approximately $60 million in channel inventory driven by factors resulting from the COVID-19 pandemic.
  • Gross margin was 49.4 percent of revenue (reported), or 50.1 percent of revenue (adjusted).
  • Earnings per share (EPS) was $(0.12) (reported), or $0.13 (adjusted).
  • Bayer Animal Health acquisition remains on track for mid-year close; Antitrust approval process progressing; new members of expanded executive leadership team announced.
  • Long-term industry fundamentals remain intact; 2020 guidance withdrawn due to uncertainty of the duration and magnitude of impacts from the COVID-19 pandemic.

Media Contact:
Colleen Parr Dekker
(317) 989-7011
colleen_parr_dekker@elanco.com

Investors Contact:
Jim Greffet
(317) 383-9935
greffet_james_f@elanco.com

General Inquiries

Elanco Animal Health
2500 Innovation Way
Greenfield, IN 46140 USA

1-877-ELANCO1

(1-877-352-6261)

Media Contacts

Questions?
Contact us.



Our Global Offices

Follow Elanco

About Elanco

Elanco (NYSE: ELAN) is a global animal health company that develops products and knowledge services to prevent and treat disease in food animals and pets in more than 90 countries. With a 64-year heritage, we rigorously innovate to improve the health of animals and benefit our customers, while fostering an inclusive, cause-driven culture for more than 5,800 employees. At Elanco, we’re driven by our vision of food and companionship enriching life – all to advance the health of animals, people and the planet. Learn more at www.elanco.com.

Coronavirus